Benitec Biopharma (BNTC) Revenue (2019 - 2023)

Benitec Biopharma (BNTC) posted Revenue of $7000.0 for Q2 2023, down 87.04% sequentially from $54000.0 in Q1 2023.

Benitec Biopharma (BNTC) Revenue (2019 - 2023) Analysis & Trends

Benitec Biopharma has reported Revenue for 5 years, with the latest figure at $7000.0 in Q2 2023.

Quarterly Revenue changed N/A year-over-year to $7000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $7000.0 (down 89.71% YoY) and the FY2023 annual result came in at $75000.0, up 2.74% from the prior year.
Revenue fell to $7000.0 in Q2 2023 per BNTC's latest filing, from $54000.0 in the prior quarter.
Over five years, Revenue peaked at $77000.0 in Q4 2019 and troughed at -$35000.0 in Q2 2020.
A 5-year average of $23846.2 and a median of $25000.0 in 2021 frame the typical range for Revenue.
The sharpest annual moves came in 2020 and 2022: Revenue tumbled 98.7% in 2020, then surged 4700.0% in 2022.
Over 5 years, Revenue stood at $77000.0 in 2019, then sank by 98.7% to $1000.0 in 2020, then jumped by 2400.0% to $25000.0 in 2021, then slumped by 44.0% to $14000.0 in 2022, then slumped by 50.0% to $7000.0 in 2023.
According to Business Quant data, Revenue over the past three periods registered $7000.0, $54000.0, and $14000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Benitec Biopharma	577.39 Mn	388.49 Mn	-	-

Download Data